Nuvalent, Inc. (NUVL)

Market Cap	6.48B
Revenue (ttm)	n/a
Net Income (ttm)	-224.29M
Shares Out	71.05M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	255,130
Open	91.35
Previous Close	91.06
Day's Range	90.28 - 92.22
52-Week Range	59.99 - 113.51
Beta	1.33
Analysts	Strong Buy
Price Target	112.60 (+23.51%)
Earnings Date	Nov 12, 2024

About NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 29, 2021
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: NUVL
• Website: https://www.nuvalent.com

Analyst Forecast

According to 10 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price forecast is $112.6, which is an increase of 23.51% from the latest price.

Price Target

$112.6

(23.51% upside)

Analyst Consensus: Strong Buy